Amicus Announces Positive Results From Clinical Trials Of Amigal For Fabry Disease

Armen Hareyan's picture
Advertisement

Amicus Therapeutics announced positive results from its recently completed Phase 2 clinical trials of Amigal (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

Advertisement